Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia

Blood

Volumn 101, Issue 2, 2003, Pages 673-680

  Harada, Hironori ^a   Harada, Yuka ^a   Tanaka, Hideo ^a   Kimura, Akiro ^a   Inaba, Toshiya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; NIMUSTINE; PREDNISOLONE; RANIMUSTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AML1 GENE; ARTICLE; ATOMIC BOMB; BINDING KINETICS; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA BINDING; DOSE RESPONSE; DOWN REGULATION; FEMALE; GENE; GENE FREQUENCY; GENETIC CODE; GERM LINE; HEMATOPOIETIC STEM CELL; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; POINT MUTATION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; SOMATIC MUTATION; TREATMENT OUTCOME;

EID: 0037438508     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1010     Document Type: Article

References (37)

1. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
2. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA. 1996;93:3444-3449.
3. Sasaki K, Yagi H, Bronson RT, et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor β. Proc Natl Acad Sci U S A. 1996;93:12359-12363.
4. Wang Q, Stacy T, Miller JD, et al. The CBFβ subunit is essential for CBFα2 (AML1) function in vivo. Cell. 1996;87:697-708.
5. Niki M, Okada H, Takano H, et al. Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor. Proc Natl Acad Sci U S A. 1997;94:5697-5702.
6. Downing JR. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol. 1999;106:296-308.
7. Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol. 1995;15:1974-1982.
8. Osato M,Asou N,Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2αB gene associated with myeloblastic leukemias. Blood. 1999;93:1817-1824.
9. Imai Y, Kurokawa M, Izutsu K, et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood. 2000;96:3154-3160.
10. Preudhomme C,Warot-Loze D, Roumier C, et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood. 2000;96:2862-2869.
11. Song W-J, Sullivan MG, Legare RD, et al. Haplo-insufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genet. 1999;23:166-175.
12. Buijs A, Poddighe P, van Wilk R, et al. A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood. 2001;98:2856-2858.
13. Bravo J, Li Z, Speck NA, Warren AJ. The leukemia-associated AML1 (Runxl)-CBFβ complex functions as a DNA-induced molecular clamp. Nat Struct Biol. 2001;8:371-378.
14. Tahirov TH, Inoue-Bungo T, Morii H, et al. Structural analysis of DNA recognition by the AML1/ Runx-1 runt domain and its allosteric control by CBFβ. Cell. 2001;104:755-767.
15. Berardi MJ, Sun C, Zehr M, et al. The Ig fold of the core binding factor alpha Runt domain is a member of a family of structurally and functionally related Ig-fold DNA-binding domains. Structure Fold Des. 1999;7:1247-1256.
16. Nagata T, Gupta V, Sorce D, et al. Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain. Nat Struct Biol. 1999;7:615-619.
17. Stanulla M, Wang J, Chervinsky DS, Aplan PD. Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus. Leukemia. 1997;11:490-496.
18. Deininger MWN, Bose S, Gora-Tybor J, Yan X-H, Goldman JM, Melo JV. Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res. 1998;58:421-425.
19. Roulston D, Espinosa R III, Nucifora G, et al. CBFA2 (AML 1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood. 1998;92:2879-2885.
20. Hromas R, Shopnick R, Jumean HG, Bowers C, Varella-Garcia M, Richkind K. A novel syndrome of radiation-associated acute myeloid leukemia involving AML1 gene translocations. Blood. 2000;95:4011-4013.
21. Finch SC. Radiation-induced leukemia [letter]. Blood. 2001;97:1897.
22. Roesch WC. US-Japan joint reassessment of atomic bomb radiation dosimetry in Hiroshima and Nagasaki, final report. Vol 1. Hiroshima, Japan: Radiation Effects Research Foundation; 1987.
23. Roesch WC. US-Japan joint reassessment of atomic bomb radiation dosimetry in Hiroshima and Nagasaki, final report. Vol 2. Hiroshima, Japan: Radiation Effects Research Foundation; 1987.
24. Bennett JM, Catovsky D, Daniel M-T, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol. 1991;78:325-329.
25. Kingston RE, Chen CA, Okayama H, Rose JK. Transfection of DNA into eukaryotic cells. In: Ausubel FM, Brent R, Kingston RE, More DD, Sejdman JG, Smith JA, Struhl K, eds. Current Protocols in Molecular Biology. New York, NY: Greene Publishing Associates and Wiley Interscience; 1996:9.1.1-9.1.11.
26. Zhang D-E, Hetherington CJ, Meyers S, et al. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBFα2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol. 1996;16:1231-1240.
27. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 1991;19:2499.
28. Harada Y, Harada H, Downing JR, Kimura A. A hematopoietic-specific transmembrane protein, Art-1, is possibly regulated by AML1. Biochem Biophys Res Commun. 2001;284:714-722.
29. Kato H, Shimizu Y. Cancer mortality rates in atomic bomb survivors. In: Shigematsu I, Ito C, Kamada N, Akiyama M, Sasaki H, eds. Effects of A-Bomb Radiation on the Human Body. Tokyo, Japan: Bunkodo; 1995:26-39.
30. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059-1064.
31. Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndrome. Semin Hematol. 1996;33:127-138.
32. Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol. 2001;73:429-437.
33. Langlois RG, Bigbee WL, Kyoizumi S, et al. Evidence for increased somatic cell mutations at the glycophorin A locus in atomic bomb survivors. Science. 1987;236:445-448.
34. Kyoizumi S, Akiyama M, Cologne JB, et al. Somatic cell mutations at the glycophorin A locus in erythrocytes of atomic bomb survivors: implications for radiation carcinogenesis. Radiat Res. 1996;146:43-52.
35. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542-3552.
36. Christiansen DH, Anderson MK, Pedersen-Biergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001;19:1405-1413.
37. Otto F, Kanegane H, Mundlos S. Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat. 2002;19:209-216.